AФArray В. Филин

Array В. Филин

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Array В. Филин has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ultrasound elastography/elastometry and steatometry in liver transplantation

    by Yu. R. Kamalov, E. Yu. Kryzhanovskaya, A. V. Filin, V. A. Sandrikov

    Background. Currently, liver transplantation remains the most effective method of treating mostly the advanced stages of chronic diffuse liver diseases. The success of liver transplantation depends, in particular, on the adequate choice of a donor liver, timely diagnosis of diffuse changes in the liver graft. In recent years, numerous reports have been published on the use of ultrasound elastometry/elastography and steatometry in the examination of patients with chronic diffuse liver diseases; and there are significantly fewer publications on the use of these methods in liver transplantation. Objective. To summarize current data on the use of ultrasound elastometry/elastography and steatometry at various stages of liver transplantation. Material and methods. The analysis of data from foreign and native studies on the use of various methods of ultrasound elastometry/elastography and steatometry in the pre- and postoperative periods during liver transplantation has been performed. The literature data was searched in international databases (PubMed/MedLine/ResearchGate) and in the scientific electronic library of Russia (eLIBRARY.RU) for the period from 2006–2024. Conclusion. The analyzed publications show the high informative value of ultrasound elastometry/elastography and steatometry in detecting fibrosis and steatosis in donor and transplanted livers, and capabilities of these methods in acute liver transplant rejection.

  • Open Access

    Hepatocellular carcinoma in children and adolescents: results of a retrospective analysis

    by S. B. Babakhanova, D. G. Akhaladze, R. A. Moiseenko, L. L. Rabaeva, P. A. Levin, А. V. Metelin, A. P. Shapochnik, A. N. Zaychikov, D. M. Konovalov, V. Yu. Roshchin, et al.

    Hepatocellular carcinoma (HCC) is a rare primary liver malignancy in children and adolescents with poor prognosis. The aim of the study – to evaluate the clinical characteristics, treatment strategies, and outcomes in pediatric and adolescent patients with HCC, and to identify factors influencing survival. Materials and methods . A retrospective analysis was conducted on 39 patients aged 4 to 16 years with histologically confirmed HCC treated and consulted at the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology between 2012 and 2023. Demographic and clinical features, underlying predisposing conditions, laboratory findings, intrahepatic tumor spread (PRETEXT staging), surgical interventions, and systemic treatment regimens were analyzed. Results. Median age was 133.5 months (11.1 years; range 49.7–199.4 months). Male to female ratio was 1.1:1. HCC developed de novo in 77 % of patients, while 23 % had predisposing conditions – most commonly chronic hepatitis B. The clinical presentation was predominantly non-specific, and in 28.9 % of cases, the tumor was discovered incidentally. Serum alpha-fetoprotein levels were within normal limits in 45% of patients, particularly in those with fibrolamellar HCC. Advanced intrahepatic tumor spread (PRETEXT stage III–IV) was observed in 60 % of cases, and distant metastases were present in 18 % of patients. The 5-year overall survival (OS) was 37 %, and the event-free survival was 26 %. The presence of distant metastases was significantly associated with inferior outcomes (5-year OS: 45 % in non-metastatic vs. 0 % in metastatic cases, p < 0.001). PRETEXT stage and histological subtype showed no significant impact on OS or event-free survival. Surgical treatment (hepatic resection or orthotopic liver transplantation) was performed in 66 % of patients and was significantly associated with improved outcomes: 5-year OS was 54 % in the surgical group versus 0 % in those who did not undergo surgery (p < 0.001). Liver transplantation showed a trend toward better outcomes compared to resection, although the difference was not statistically significant. Initial treatment strategy (primary resection vs. biopsy with neoadjuvant chemotherapy) had no impact on survival. Conclusion s. Pediatric HCC is a rare but highly aggressive malignancy that is often diagnosed at an advanced stage. Radical surgical resection, including liver transplantation in certain cases, remains the primary determinant of prognosis. Improved outcomes require early diagnosis, early discussion of therapeutic tactics in center specialized in hepatobiliary surgery and inclusion of pediatric patients in multicenter clinical trials.

  • Open Access

    Results of treatment of patients with high and very high risk hepatoblastoma

    by R. A. Moiseenko, D. G. Akhaladze, A. V. Filin, M. Ya. Yadgarov, E. F. Kim, G. S. Rabaev, E. V. Feoktistova, N. N. Merkulov, A. V. Metelin, G. V. Tereshchenko, et al.

    Background. Hepatoblastoma (HB) is the most common malignant liver tumor in children aged 0–14 years. The introduction of intensive therapy based on alternating courses of cisplatin and carboplatin/doxorubicin, as well as dose-compression regimens of cisplatin administration, has significantly improved the prognosis in high-risk patients.The aim of the study – to assess the effectiveness of therapy in high-risk (HR) and very high-risk (VHR) patients with HB treated according to the International Group for Optimization of Therapy in Pediatric Liver Tumors (SIOPEL) protocols based on 2 major medical centers in the Russian Federation.Materials and methods. The study included patients with a verified diagnosis of HR and VHR HB, who received therapy at Dmitry Rogachev National Medical Research Center of the Pediatric Hematology, Oncology and Immunology and B.V. Petrovsky Russian Scientific Center of Surgery for the period 02.2012 to 07.2022 (125 months). The criteria of the SIOPEL group were used to stratify into risk groups. Until 2017, all patients were stratified into the HR group and received treatment according to the SIOPEL-4 protocol; since 2017, differentiated therapy has been carried out for patients in the HR group (SIOPEL-3 HR protocol) and VHR (SIOPEL-4 protocol). Since 2017, patients over 8 years of age have been stratified into VHR group. Survival was estimated using the Kaplan–Meier method. This study assessed overall survival (OS), event-free survival (EFS), and cumulative probability of death. Survival analysis was carried out as of 01.08.2023.Results. 49 patients with HR and VHR group HB aged 0 to 13 years were registered. The analysis included 47/49 (95.9 %) patients who received therapy according to the SIOPEL protocols. The median age at diagnosis was 24.9 months (range – 4.7–154.9). The male: female ratio was 1.47:1. Distribution by PRETEXT stage: PRETEXT II – 13 (27.6 %), PRETEXT III – 18 (38.3 %), PRETEXT IV – 16 (34.1 %) patients. The median α-fetoprotein level in patients with known exact values (n = 45) at the time of diagnosis was 182 431 (0.85–1 998 000) ng/ml. 24/47 (51 %) patients had initial lung metastases. The extent of delayed surgery: resection – 32 (68.1 %) patients, transplantation – 12 (25.5 %), without delayed surgery – 3 (6.4 %). Radicality of delayed surgery: R0 – 41/47 (87.2 %) patients, R1 – 3/47 (6.4 %), in 3/47 (6.4 %) patients the surgery wasn’t performed. Median follow-up 39.2 (2.5–129.2) months. Of the 47 patients included in the study, 37 (78.7 %) are alive, 10 (21.3 %) died (2/10 – surgical complications, 1/10 – infectious complications, 7/10 – progression of HB). Relapses/progressions were observed in 14/47 (29.8 %) patients, 7 (50 %) of whom died from disease progression. 3-year OS and EFS of the whole cohort (n = 47) were 80.1 ± 6.0 % and 64.9 ± 7.1 %. In the group of patients after liver transplantation (n = 12), 3-year OS and EFS were 73.3 ± 13.2 % and 64.2 ± 14.4%. The 3-year cumulative probability of death from the tumor was 16.7 ± 5.8 %. The 3-year cumulative probability of death from other causes was 7.2 ± 4.0 %. 3-year OS and EFS in the group of patients with distant metastases were 76.5 ± 9.4 % and 57.1 ± 10.3 %, in the group of patients without metastases 77.6 ± 8.8 % and 73.0 ± 9.4 %, respectively (p = 0,919 for OS; р = 0,440 for EFS).Conclusions. The data obtained in the study are consistent with the original studies of the SIOPEL group. The feasibility and effectiveness of incorporating liver transplantation into the treatment of patients with HB in the HR and VHR groups was confirmed.

  • Open Access

    Goal-oriented therapy of coagulopathy in liver transplantation in children (literature review)

    by D. I. Novikov, A. Yu. Zaitsev, A. V. Filin, A. V. Metelin, А. Ю. Зайцев

    Introduction. Methods for correcting perioperative blood loss and hemostasis disorders in children during liver transplantation are still controversial and are largely conducted empirically by specialists. Additional difficulties are imposed by the features of a continuously growing and developing organism, as well as the following hemostasis system.The objective was to analyze modern approaches to the correction of hemostasis disorders in children in the perioperative period of liver transplantation.Materials and methods. The analysis of literary sources indexed for the period from 2000 to 2024 in the databases PubMed, Google Scholar, Cochrane MEDLINE and E-Library (for Russian authors).Results. The analysis of the literature has shown that at present, in liver transplantation in children, a personalized approach prevails in choosing the tactics of infusion – transfusion therapy and correction of developing changes in the hemostasis system. Modern approaches are aimed at the fastest possible identification of specific perioperative disorders of pro- and anticoagulant factors directly «at the patient’s bedside» and targeted correction of each specific element.Conclusion. Despite the active development and improvement of approaches to correcting perioperative hemostasis disorders during liver transplantation, improving pharmacotherapy protocols, minimizing the time to obtain laboratory data and reducing the influence of the human factor on the interpretation of results and treatment choice, the study of the hemostasis system and correction of its disorders is still very far from the final stage.

  • Open Access

    Surgical stage of treatment of hepatoblastoma in patients with ventriculoperitoneal shunt: results of two clinical case

    by A. A. Babayan, A. V. Filin, A. V. Metelin, N. A. Koroteeva, O. V. Kazakova, A. Yu. Zaitsev, R. B. Mayachkin, D. I. Novikov, V. B. Silkov

    Hepatoblastoma is considered the most common malignant tumor with a stable tendency towards increased incidence in children. Prematurity is recognized as one of the significant risk factors associated with its development. Prematurity often coexists with a wide range of comorbid conditions, particularly in cases of deep prematurity stage IV. Such children are predisposed to a significant risk of intraventricular bleeding and chronic lung conditions, including bronchoalveolar dysplasia. The incidence of intraventricular bleeding is estimated to be between 20–40 %, while bronchoalveolar dysplasia ranges from 35–80 %. In cases of hepatoblastoma in premature children with these comorbid conditions, the surgical management stage (which typically includes chemotherapy) carries additional risks. There is limited data available regarding abdominal surgery in such patients, and notably, there have been no documented examples of extensive liver resections in this population. In this article, we will discuss two clinical cases detailing the surgical management of children with prematurity.

  • Open Access

    Infusion-transfusion therapy and correction of water–electrolyte disorders in simultaneous liver fragment transplantation and kidney retransplantation (clinical case)

    by D. I. Novikov, A. Yu. Zaitsev, O. E. Kut’iNa, A. V. Filin, A. K. Zokoev, A. V. Metelin, S. V. Shchkaturov, M. Ya. Khalimov, А. Ю. Зайцев, М. Я. Халимов

    A clinical case of simultaneous surgery in the volume of transplantation of the left lateral sector of the liver and kidney retransplantation from one living related donor to a 10-year-old girl with cirrhosis of the liver and after transplantectomy of the donor kidney is presented. The child born in 2013 was transferred to program hemodialysis in 2015 as a result of the development of end-stage chronic kidney disease (CKD) in the outcome of congenital kidney dysplasia. In October 2022, renal replacement therapy was started as a result of a relapse of end-stage CKD. In January 2023, she suffered purulent cystitis. 02.24.2023 – transplantectomy. 05.05.2023, simultaneous transplantation of the left lateral sector of the liver and kidney allotransplantation from a living related donor were performed. Anesthesiologists faced a serious problem in the form of the selection of adequate infusion therapy, taking into account the combination of two surgical interventions that radically differ in the tactics of anesthesiological support, as well as the correction of water – electrolyte disorders in the complete absence of diuresis throughout the fifteen-hour surgical intervention

  • Open Access

    Prosthetics of the inferior vena cava in children with hepatoblastoma: a literature review and our own results

    by A.V. Filin, E.R. Charchyan, A.V. Metelin, T.N. Galyan, V.V. Khovrin, Yu.R. Kamalov, R.I. Pimenov, Moscow Morozov Children’s City Clinical Hospital, R.B. Mayachkin, O.V. Kazakova, et al.

    Протезирование нижней полой вены у детей с гепатобластомой: обзор литературы и собственные результаты

  • Open Access

    Effectiveness of cisplatin monotherapy in standard-risk hepatoblastoma

    by R. A. Moiseenko, D. G. Akhaladze, A. V. Filin, E. F. Kim, G. S. Rabaev, E. V. Feoktistova, N. N. Merkulov, A. V. Metelin, G. V. Tereshchenko, V. V. Shchukin, et al.

    Risk-adapted therapy is the standard of care for hepatoblastoma (HB). The aim of this study was to analyze the effectiveness of cisplatin monotherapy in patients with standard-risk HB. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. For the period 02.2012–12.2019 (95 months) 60 patients with standard-risk HB aged 0–8 years were treated within the framework of the cooperation of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation and B.V. Petrovsky Russian Scientific Center of Surgery. The SIOPEL criteria were used for stratification into risk groups. Throughout the study period, standard-risk patients received therapy per SIOPEL-3 SR protocol, including cisplatin monotherapy. Survival was assessed by the Kaplan–Meier method. For the purposes of this study, overall survival (OS), event-free survival (EFS), where any modification of chemotherapy regimen towards its escalation were considered as an additional event, and progression-free survival (PFS) were calculated. The survival analysis was carried out on 15.01.2021; 54/60 (90%) patients were treated with cisplatin monotherapy and included in the final analysis. Median age at diagnosis was 11.3 (range 0.0–87.7) months. Male:female ratio – 0.86:1. Distribution by PRETEXT stages: I – 14 (25.9%), II – 30 (55.6%), III – 10 (18.5%) patients. The median alphafetoprotein level at the time of diagnosis was 162 979 (range 129–2 000 000) ng/ml. Modification of therapy without confirmed relapse/progression was required in 3/54 patients. Median follow-up was 47.1 (range 2–99) months. Among 54 patients 52 (96.3%) are alive, 2 (3.7%) patients died (1/2 – complications of surgical treatment). Relapses/progressions were noted in 4/54 (7.4%) patients, one of whom died due to disease progression. The three-year OS was 98.1% (95% confidence interval (CI) 94.6–100), EFS – 85.1% (95% CI 75.5–94.6), PFS – 90.5% (95% CI 82.5–98.4). Our data are consistent with the original studies of the SIOPEL group and convincingly confirm the effectiveness of cisplatin monotherapy in patients with HB of the standard risk group in the Russian Federation. Currently this regimen is incorporated into the national clinical guidelines of HB therapy and considered as a standard of care.


  • Open Access

    The system for assessing liver function according to magnetic resonance imaging with gadoxetic acid

    by D. E. Somova, T. N. Galyan, A. S. Kulichkin, A. V. Filin, V. V. Khovrin

    Purpose. To develop a system for assessing liver function in patients with liver cirrhosis according to magnetic resonance imaging (MRI) with gadoxetic acid.Material and Methods. Data from studies of 74 patients who underwent abdominal MRI with intravenous gadoxetic acid (GA) enhancement were analyzed. For statistical analysis of the data, two groups were formed: group 1 (n = 22) comprised patients with unchanged liver parenchyma, normal liver function, and benign tumors; group 2 (n = 52) comprised patients with liver cirrhosis, with the presence of regenerative and/or dysplastic nodes, and hepatocellular carcinoma (HCC). The following quantitative parameters were studied to assess liver function in patients of two groups: relative enhancement (RE), contrast enhancement index (CEI), liver/skeletal muscle (SM) index, liver/spleen index, liver/kidney index, analysis of histograms (AH), and liver function imaging scale (FLIS).Results. The criteria for a functional deficiency of liver function based on calculated data of contrast agent transport and accumulation were a decrease in FLIS total score to 4 and below, RE values below 0.85, and CEI values below 1.38 with sensitivity and specificity of 100 and 75%, the values of liver/SM and liver/kidney indices below 0.350, liver/spleen index below 0.750 with sensitivity and specificity of 100 and 81%, respectively, in patients with cirrhosis.Conclusion. The developed system for assessing liver function using FLIS, intensity matching analysis (IMA), and AH according to MRI with GC in comparison with METAVIR allowed for liver function assessment in patients with cirrhosis with a sensitivity and specificity of 100% and 80%, respectively.

  • Open Access

    Abernethy Malformation in Children with Focal Liver Lesions

    by D. E. Arutyunyants, V. V. Khovrin, T. N. Galyan, A. S. Kulichkin, A. V. Filin, E. Yu. Kryzhanovskaya

    Abernethy malformation is a congenital disease characterized by complete or partial underdevelopment of the portal vein, leading to the occurrence of congenital extrahepatic portosystemic shunts. The anomaly with the absence of the portal vein is detected in 80% of cases in childhood. Patients with this pathology are very frequently examined when detecting space-occupying liver lesions and assuming the presence of a vascular abnormality. The paper describes clinical cases of benign focal liver lesions and Abernethy malformation in children.